Seres Therapeutics Announces Closing of Initial Public Offering

July 01, 2015 04:05 PM Eastern Daylight Time

CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the closing of
its initial public offering of 8,545,138 shares of its common stock at
an initial public offering price of $18.00 per share, which includes the
exercise in full by the underwriters of their option to purchase
1,114,583 additional shares of common stock. The shares began trading on
the NASDAQ Global Select Market under the ticker symbol "MCRB" on June
26, 2015. All of the shares of common stock in the offering were offered
by the company. The net proceeds to Seres Therapeutics from the sale of
shares in the offering are estimated to be approximately $139.8 million,
after deducting the underwriting discounts and estimated offering
expenses.

Goldman, Sachs & Co. and BofA Merrill Lynch acted as joint book-running
managers for the offering, and Leerink Partners and Canaccord Genuity
Inc. acted as lead managers for the offering.

A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on June 25, 2015.
This offering was made only by means of a prospectus. Copies of the
final prospectus relating to this offering may be obtained by contacting
Goldman, Sachs & Co. by mail at 200 West Street, New York, New York
10282, Attention: Prospectus Department, by telephone at (866) 471-2526,
or by email at prospectus-ny@ny.email.gs.com
or BofA Merrill Lynch, by mail at 222 Broadway, New York, New York
10038, Attention: Prospectus Department, or by email at dg.prospectus_requests@baml.com.

This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such state or jurisdiction.